Bristol-Myers Squibb (BMY)

Whichever one you choose, you'll need patience before you can see solid returns.

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive results from prespecified interim analyses of two Phase 3 studies evaluating izalontamab brengitecan (iza-bren), an investigational and potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC). The studies demonstrated iza-bren achieved statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC; PANKU-Breast02/BL-B01D1-307) and recurrent or metastatic esophageal squamous cell carcinoma (ESCC; PANKU-Esophagus01/BL-B01D1-305). These data, presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, support iza-bren’s potential as a new standard of care in these challenging cancer types.

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). If approved, Camzyos would be the first cardiac myosin inhibitor (CMI) to treat adolescents with oHCM. The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) date of September 30, 2026. Camzyos is currently approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III oHCM to improve functional capacity and symptoms and has been prescribed by more than 4,500 healthcare providers (HCPs) to almost 25,000 patients in the U.S. alone.

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and adolescent patients 12 years of age and older with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL). This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the first immunotherapy-based regimen available in the European Union (EU) for newly diagnosed advanced cHL.1

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Bristol Myers Squibb (NYSE: BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Results showed MeziKd demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS) (95% CI: 18 months vs. 8.3 months [HR:0.48; p<0.0001]), representing a 52% reduction in the risk of disease progression or death compared with Kd.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

The numbers don't tell the full story with this big pharma stock.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 29 – June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company will highlight progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies.

The market appears to be short-sighted.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Bristol Myers Squibb (NYSE:BMY, "BMS"), a global biopharmaceutical leader, today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions. The collaboration signals a meaningful evolution in how BMS deploys AI, moving beyond conversational tools that have defined the first wave of enterprise adoption, toward agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations.

These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them.

What happens when you actually do the thing most investors only talk about and hold stocks for a full decade?

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin...

This may be an excellent deal for those focused on the long game.

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independe

Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy. Sotyktu, a once-daily oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for the treatment of active PsA in the European Union (EU).

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product...

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026.